Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Novartis closed its $9.7 billion acquisition of The Medicines Company in January 2020, picking up inclisiran (a Phase 3 siRNA targeting PCSK9 jointly developed…
On April 13, 2020, Alnylam Pharmaceuticals, Inc. entered into a series of agreements with Blackstone affiliates: a Royalty Purchase Agreement (50% of royalties…
Alnylam reported its first profitable full year in 2025: total net product revenue $2.987B (+81% YoY), led by AMVUTTRA $2.314B (driven by US ATTR-CM demand),…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
Blackstone and Alnylam entered a $2B strategic financing collaboration. Blackstone Life Sciences purchased 50% of Alnylam's inclisiran royalties and commercial milestones for $1B and committed up to $150M for vutrisiran and ALN-AGT R&D, plus $100M equity. GSO Capital Partners provided up to $750M senior secured term loan. One of the largest private biotech financings ever.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Blackstone Group Inc. / Alnylam Pharmaceuticals Inc. (this deal) | 2020 | $2.0B | — |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Astra AB / Zeneca Group plc | 1998 | $35.0B | 94 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
← Browse all deals · How we score deals
More: 2020 deals · Cardiovascular deals